Results 111 to 120 of about 8,657 (176)

Checkpoint Inhibitor-Induced Raynaud's Phenomenon, Hypothyroidism, and Pneumonitis in Head and Neck Cancer: A Case Report. [PDF]

Cureus
Bodoki L, Csonka T, Szekanecz Z, Szamosi S, Major NA, Szekanecz É.   +5 more
europepmc   +1 more source

An epidemiological study estimating the burden of cancer risk in patients with Raynaud's phenomenon. [PDF]

Clin Rheumatol
Hughes M, Jude E, McMahan ZH, Alam U, Ruaro B, Zhao SS.   +5 more
europepmc   +1 more source

Primary Raynaud's Phenomenon. [PDF]

J Community Hosp Intern Med Perspect
Alweis EA, Alweis RL.
europepmc   +1 more source

Identifying candidate core domains for clinical trials in systemic sclerosis-associated Raynaud's phenomenon and digital ulcers. [PDF]

Semin Arthritis Rheum
Proudman SM, Hughes M, Maltez N, Brown E, Hickey V, Quinn KA, Christensen R, Shea B, Herrick AL, Pauling JD, Merkel PA, OMERACT Scleroderma Vascular Disease Working Group.   +11 more
europepmc   +1 more source

Is Low-Level Laser Therapy an Effective Treatment for Patients with Primary Raynaud’s Phenomenon?

, 2012
OBJECTIVE: The objective of this selective EBM review is to determine whether or not low-level laser therapy is an effective treatment for patients with primary Raynaud’s Phenomenon.
Ruiz, Adriana S
core  

Complete relief of a severe feet and hand necrotising Raynaud’s phenomenon with double cervical and dorsal spinal cord stimulation

, 2017
Rationale of the study Several evidences suggest that spinal cord stimulation (SCS) can effectively treat vascular disorders. Raynaud’s phenomenon is a vaso- spastic condition affecting primarily the distal resistance vessels. Usually it is triggered by
Puntillo F., Preziosa A., Giglio M., Bruno F., Iannone F.   +4 more
core  

Novel pleiotropic loci link vascular and immune pathways in systemic sclerosis and primary Raynaud's phenomenon. [PDF]

Rheumatology (Oxford)
Rangel-Peláez C, Rodriguez-Martin I, Rosa-Baez C, Kerick M, Guillén-Del-Castillo A, Simeón-Aznar CP, Callejas JL, Distler O, Proudman SM, Nikpour M, Hunzelmann N, Moroncini G, de Vries-Bouwstra JK, Herrick AL, Allanore Y, Alarcón-Riquelme ME, Beretta L, Mayes MD, Denton CP, Assassi S, Martín J, Acosta-Herrera M, Ortiz-Fernández L, and the International SSc Group, the PRECISESADS Clinical Consortium, and the Australian Scleroderma Interest Group (ASIG)# .   +25 more
europepmc   +1 more source

Infrared thermography for the diagnosis and monitoring of Raynaud's phenomenon: current evidence and future directions. [PDF]

Reumatologia
Patil H, Monisha IN, Mallikarjunaswamy MS, Praveen P, Sowmya MS, Chandra MN, Mamadapur M.   +6 more
europepmc   +1 more source

Audiovestibular Manifestations in Patients with Primary Raynaud's Phenomenon and Raynaud's Phenomenon Secondary to Systemic Sclerosis. [PDF]

J Clin Med, 2023
Amor-Dorado JC, Martín-Sanz E, Franco-Gutiérrez V, Urruticoechea-Arana A, García-Arumí AM, Racines-Álava E, Alemán-López O, Simeón-Aznar CP, González-Gay MÁ.   +8 more
europepmc   +1 more source

Validation of the Turkish version of the assessment of systemic sclerosis-associated Raynaud's phenomenon (ASRAP). [PDF]

Turk J Med Sci
Temiz Karadağ D, Yilmaz Ş, Dikkanoğlu Demirok B, Pauling JD, Yazici A, Çefle A.   +5 more
europepmc   +1 more source